Last updated: February 22, 2026
What Is NDC 31722-0143?
NDC 31722-0143 is a prescription pharmaceutical product marketed under Eli Lilly’s Trulicity (dulaglutide). It is a GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes. The drug is administered via weekly injection.
Market Overview
Current Market Size
The global market for GLP-1 receptor agonists, including Trulicity, was valued at approximately $15 billion in 2022, with expectations to grow at a CAGR of about 13-15% over the next five years. The U.S. accounts for roughly 50% of sales, driven by high prevalence rates of type 2 diabetes and expanding insurance coverage.
Competitive Landscape
Major competitors include:
- Ozempic (semaglutide) – Novo Nordisk
- Rybelsus (oral semaglutide) – Novo Nordisk
- Bydureon (exenatide) – AstraZeneca
- Farxiga (dapagliflozin) – AstraZeneca (used off-label in some cases)
Regulatory Status
- FDA approval: Approved in 2014.
- European approval: Approved since 2015.
- Growth driven by expanding indications, including use in obesity management.
Pricing Landscape
Current Pricing
- U.S. retail list price for Trulicity (per 4.5 mg dose): approximately $974 per month (source: GoodRx).
- Average wholesale price (AWP): around $620–$650 per pen (week supply).
Reimbursement & Discount Trends
- Actual transaction prices often reduce by 10-25% through discounts, rebates, and insurance negotiations.
- The net price per pen generally falls within $465–$520.
Price Projections and Future Trends
Factors Affecting Price
- Patent expiration: U.S. patent expired in May 2030, opening potential for biosimilar entry.
- Biosimilar Competition: Entry expected within 2-3 years post-patent expiry; biosimilars typically price at a 20-30% discount.
- Manufacturing costs: Slight decreases expected as process efficiencies improve.
- Market penetration: Increasing adoption in obesity and cardiovascular indications may sustain premium pricing.
Short-term (Next 1–2 Years)
- No significant price reductions anticipated before patent expiry.
- Reimbursement rates are likely to stabilize or slightly decline due to payer negotiations.
- List price may increase annually by about 3-5%, consistent with inflation and manufacturer pricing policies.
Long-term (Post-Patent)
- Biosimilar entrants could reduce net prices by 20–30%.
- Price erosion may accelerate in the 3–5 year window after biosimilar launches.
- Competitive pressure from alternative therapies (e.g., oral agents, SGLT2 inhibitors) may impact formulas’ pricing strategies.
Estimated Price Trajectory
| Year |
List Price (monthly) |
Net Price (after discounts) |
Market Share Impact |
| 2023 |
$974 |
$520 |
Steady, no significant change |
| 2024 |
$1,020 |
$530 |
Slight increase, stable |
| 2025 |
$1,070 |
$535 |
Anticipate patent expiration, slight decline |
| 2026+ |
Decline to $800–$900 (biosimilars) |
<$400 (biosimilar competition) |
Prices expected to decline significantly post-patent |
Potential Market Dynamics Influencing Price
- Physician and patient preferences shifting toward oral therapies may influence the market share and pricing.
- Insurance formularies could favor biosimilars once available, pressuring list prices.
- Regulatory decisions affecting extended indications may increase revenue, justifying premium pricing.
Strategic Considerations
- Lilly may maintain premium pricing through novel formulations or expanded indications.
- Market entry of biosimilars will drive price erosion but may also lead to increased overall market volume.
- Diversification into obesity and cardiovascular markets could sustain revenue streams regardless of biosimilar competition.
Summary
NDC 31722-0143 (Trulicity) maintains a high list price driven by its brand strength and patent exclusivity. Price shaves are expected with biosimilar entry around 2026-2027, leading to a projected 20-30% price reduction on net prices. The market remains robust, with growth primarily driven by expanding indications and increasing adoption.
Key Takeaways
- Trulicity’s current USA list price is approximately $974/month; net prices are lower.
- The global GLP-1 class grows at ~13–15% CAGR, bolstering Trulicity’s market position.
- Patent expiry in May 2030 opens the market for biosimilars, likely leading to 20–30% price declines.
- Competition from oral and alternative therapies influences pricing and market share.
- Market expansion into obesity and cardiovascular indications may counterbalance pricing pressures.
FAQs
Q1: When do biosimilars for Trulicity likely enter the market?
A1: Biosimilar entry is expected approximately 2–3 years after patent expiration, around 2026–2027.
Q2: What impact will biosimilar entry have on price?
A2: Biosimilars are projected to cut net prices by 20–30%, increasing market accessibility and volume.
Q3: How does the market growth rate affect future pricing?
A3: A CAGR of 13–15% sustains revenue, but price reductions post-biosimilar entry may offset volume gains.
Q4: Will insurance influence the net price trend of Trulicity?
A4: Yes, insurers may negotiate discounts and favors biosimilars, influencing net price trajectories.
Q5: Are there opportunities beyond the diabetes market?
A5: Yes, expanding indications in obesity and cardiovascular conditions present growth avenues.
References
[1] IQVIA. (2022). United States Pharmaceutical Market Reports.
[2] GoodRx. (2023). Trulicity (dulaglutide) Prices and Coupons.
[3] Eli Lilly. (2023). Trulicity Product Information.
[4] EvaluatePharma. (2022). World Preview 2027.
[5] U.S. Food and Drug Administration. (2022). Approved Drug Products: Trulicity.
